STOCK TITAN

Tempest Therapeutics, Inc. - TPST STOCK NEWS

Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.

Tempest Therapeutics, Inc. (TPST) is a biotechnology company focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways.

Tempest's mission is to pioneer novel treatments for cancer by leveraging a balanced and deep pipeline of small molecule therapeutics. These therapeutics are designed to modulate distinct immune response pathways that are crucial for mounting an effective anti-tumor response. Developed by Inception Sciences, a Versant Ventures-affiliated drug discovery engine, the company’s pipeline includes first-in-class and best-in-class molecules.

The company’s leading product candidates, TPST-1120 and TPST-1495, are in the clinical stage. TPST-1120 aims to inhibit its target to promote anti-tumor immunity, while TPST-1495 is designed to activate tumor-specific immune responses. These candidates are developed to address significant unmet medical needs across a range of cancers.

Tempest Therapeutics has assembled a highly experienced team of drug developers specializing in small molecules and immuno-oncology. This team is dedicated to advancing these programs through clinical trials and eventually to market. The company's robust research and development efforts are backed by a syndicate of leading venture capital firms based in the United States and China, providing strong financial support and strategic guidance.

Recent achievements for Tempest Therapeutics include the initiation and progress of randomized clinical trials, showcasing the company’s commitment to evidence-based development and regulatory approval. With a focus on innovation and patient outcomes, Tempest Therapeutics is well-positioned to make significant contributions to the field of oncology.

For more detailed information on the company’s latest updates, news, and financial performance, you can contact Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

Rhea-AI Summary
Tempest Therapeutics adopts limited duration stockholder rights plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics announces positive results from a Phase 1b/2 study of TPST-1120 in combination with atezolizumab + bevacizumab in the treatment of hepatocellular carcinoma (HCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics to report new data from Phase 1b/2 combination study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3970.83%
Tags
conferences
Rhea-AI Summary
Tempest Therapeutics announces expansion of role for executive VP and CMO, Sam Whiting, to include head of Research and Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
Rhea-AI Summary
Tempest Therapeutics, Inc. reported financial results for Q2 2023, including positive data from their TPST-1120 and TPST-1495 clinical programs. TPST-1120 demonstrated a 74.4% relative improvement in objective response rate (ORR) and a 69.9% relative improvement in confirmed ORR. TPST-1495 showed increased potency against prostaglandin-driven tumor models. The company expects to discuss updated data from the TPST-1120 trial in H2 2023 and report data from the TPST-1495 combination arm in 2024. Tempest ended Q2 with $17.6 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
Rhea-AI Summary
Tempest Therapeutics announces publication of in vitro and in vivo data on TPST-1495, a novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling. The data shows increased potency compared to existing drugs and supports previous clinical results of tumor shrinkage and disease control. Tempest also highlights their innovative pipeline, including TPST-1120 for first-line HCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
conferences
-
Rhea-AI Summary
Tempest Therapeutics announces Phase 1 clinical trial data for TPST-1495 to be presented at ASCO Annual Meeting. Data shows tumor shrinkage and prolonged disease control in both monotherapy and combination with pembrolizumab. Treatment well tolerated with manageable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none

FAQ

What is the current stock price of Tempest Therapeutics (TPST)?

The current stock price of Tempest Therapeutics (TPST) is $0.7116 as of December 20, 2024.

What is the market cap of Tempest Therapeutics (TPST)?

The market cap of Tempest Therapeutics (TPST) is approximately 31.1M.

What does Tempest Therapeutics, Inc. do?

Tempest Therapeutics is focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways to treat cancer.

What are Tempest Therapeutics' main product candidates?

The main product candidates are TPST-1120 and TPST-1495, which are designed to inhibit and activate specific targets to promote anti-tumor immunity.

Who developed Tempest Therapeutics' molecules?

The molecules were developed by Inception Sciences, a drug discovery engine affiliated with Versant Ventures.

What makes Tempest Therapeutics' pipeline unique?

Tempest Therapeutics' pipeline is balanced and deep, consisting of first-in-class and best-in-class molecules that modulate distinct immune response pathways.

Who are the key contacts for investor and media inquiries?

Key contacts are Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

What type of cancers does Tempest Therapeutics target?

Tempest Therapeutics targets a range of diverse cancers representing significant unmet medical needs.

What is the core mission of Tempest Therapeutics?

The core mission is to pioneer novel treatments for cancer by leveraging small molecule therapeutics that modulate anti-tumor immunity pathways.

What recent achievements has Tempest Therapeutics made?

Recent achievements include the initiation and progress of randomized clinical trials as part of their clinical development programs.

Who supports Tempest Therapeutics financially?

Tempest is backed by leading venture capital firms based in the United States and China.

How can I get the latest updates on Tempest Therapeutics?

You can get the latest updates by following the news section or contacting Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.

Tempest Therapeutics, Inc.

Nasdaq:TPST

TPST Rankings

TPST Stock Data

31.10M
43.57M
0.24%
23.02%
10.47%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE